Drug profile · INN
letibotulinumtoxina-wlbg
LETYBO
letibotulinumtoxina-wlbg (LETYBO) is a synaptosomal nerve-associated protein 25 (snap-25) hydrolytic enzyme. Current US regulatory status: approved.
Drug details — letibotulinumtoxina-wlbg
- US status
- approved
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 1
- Data quality
- 0.81
Quick answer
letibotulinumtoxina-wlbg (LETYBO) is a synaptosomal nerve-associated protein 25 (snap-25) hydrolytic enzyme. Current US regulatory status: approved.
Key facts
Mechanism of action
Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme
Primary target: Synaptosomal-associated protein 25
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is letibotulinumtoxina-wlbg?
letibotulinumtoxina-wlbg (LETYBO) is a synaptosomal nerve-associated protein 25 (snap-25) hydrolytic enzyme. Current US regulatory status: approved.
What is the brand name for letibotulinumtoxina-wlbg?
LETYBO is a marketed brand name for letibotulinumtoxina-wlbg. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of letibotulinumtoxina-wlbg?
letibotulinumtoxina-wlbg has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.